A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Mar 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bleomycin (Primary) ; Dacarbazine (Primary) ; Doxorubicin (Primary) ; Rituximab (Primary) ; Vinblastine (Primary)
Indications Hodgkin's disease
Focus Therapeutic Use

18 Sep 2018 Planned End Date changed from 1 Mar 2020 to 31 Mar 2020.
18 Sep 2018 Planned primary completion date changed from 1 Mar 2019 to 31 Mar 2019.
16 Sep 2018 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com